Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE
NCT05338450Phase 3Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) and internuclear ophthalmoplegia (INO) comparing Clemastine Fumarate with Placebo (2 arms). Primary endpoint: Versional Dysconjugacy Index - Area Under the Curve at 36 months. Started Aug 2022; status: terminated.
02
Drugs
clemastine
03
Conditions
multiple sclerosis (MS)internuclear ophthalmoplegia (INO)
Beyond the preview
Go deeper on NCT05338450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338450.